Glomerulonephritis clinical trials at UC Irvine
2 research studies open to eligible people
TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
open to eligible people ages 18 years and up
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will - take part in this study for about 19 months - Have urine tests done - Have blood samples taken - Have physical examinations done
Orange 5379513, California 5332921 and other locations
Iptacopan in Participants With IC-MPGN
open to eligible people ages 12-60
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
Orange 5379513, California 5332921 and other locations
Last updated: